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Abstract	
The	association	between	human	cytomegalovirus	(hCMV)	reactivation	and	the	development	of	
graft-versus-host-disease	(GVHD)	has	been	observed	in	stem	cell	transplantation	(SCT).		Seventy	
seven	SCT	donor-recipient	pairs	(DRP)	(HLA	matched	unrelated	donor	(MUD),	n=50;		matched	
related	donor	(MRD),	n=27)	underwent	whole	exome	sequencing	to	identify	single	nucleotide	
polymorphisms	(SNPs)	generating	alloreactive	peptide	libraries	for	each	DRP	(9-mer	peptide-
HLA	complexes);	Human	CMV	CROSS	(Cross-Reactive	Open	Source	Sequence)	Database	was	
compiled	from	NCBI;	HLA	class	I	binding	affinity	for	each	DRPs	HLA	was	calculated	by	
NetMHCpan	2.8	and	hCMV-	derived	9-mers	algorithmically	compared	to	the	alloreactive	
peptide-HLA	complex	libraries.	Short	consecutive	(≥6)	amino	acid	(AA)	sequence	homology	
matching	hCMV	to	recipient	peptides	was	considered	for	HLA-bound-peptide	(IC50<500nM)	
cross	reactivity.	Of	the	70,686	hCMV	9-mers	contained	within	the	hCMV	CROSS	database,	
29,658.8	±	9038.5	were	found	to	match	MRD	DRP	alloreactive	peptides	and	52,910.2	±	16121.8		
matched	MUD	DRP	peptides	(Student’s	T-test,	p<0.001).	In	silico	analysis	revealed	multiple	high	
affinity,	immunogenic	CMV-Human	peptide	matches	(IC50<500	nM)	expressed	in	GVHD-affected	
tissue-specific	manner	(proteins	expressed	at	≥10	RPKM).	hCMV+GVHD	was	found	in	18	
patients,	13	developing	hCMV	viremia	before	GVHD	onset	with	a	subset	analysis	of	7	instances	
of	hCMV	viremia	prior	to	acute	GVHD	onset	(n=3),	chronic	GVHD	(n=2)	and	acute	+	chronic	
GVHD	(n=2)		indicating	cross	reactive	peptide	expression	within	affected	organs	.	We	propose	
that	based	on	our	analysis	and	preliminary	clinical	correlations	that	hCMV	immune	cross-
reactivity	may	cause	antigenic	mimicry	of	human	alloreactive	peptides	triggering	GVHD.	
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Introduction	
Human	cytomegalovirus	and	other	viral	infections	pose	a	significant	hurdle	to	successful	stem	
cell	transplantation,	affecting	morbidity	and	mortality	rates	among	the	immunocompromised	
populations	the	world	over.		1,2	Human	CMV	seropositivity	has	been	estimated	in	50-80%	of	the	
population	in	the	United	States	by	age	40.		3	While	the	majority	of	infected	patients	are	
asymptomatic	due	to	viral	latency	after	initial	viral	clearance,	SCT	patients	with	newly	
reconstituted	immune	systems	exhibit	rates	of	reactivation	approximately	30-65%	in	multiple	
studies.		4-7	Furthermore,	hCMV	reactivation	tends	to	be	associated	with	the	incidence	of	
another	serious	complication	of	SCT,	i.e.,	GVHD.	Although	many	groups	have	historically	
separated	GVHD	incidence	from	hCMV	infection	data,	even	by	complete	exclusion	in	clinical	trial	
design,	there	has	been	growing	evidence	that	these	diseases	are	not	mutually	exclusive	and	are	
likely	linked	in	a	number	of	ways	beyond	treatment.		8,9		
GVHD	pathophysiology	is	driven	by	donor	T	cell	mediated	alloreactivity,	directed	against	
recipient	mHA.	These	are	recipient-derived	oligopeptides	presented	on	HLA	molecules,	and	
result	from	coding	nucleotide	sequence	variation.	Whole	exome	sequencing	has	been	used	to	
identify	the	entire	library	of	nucleotide	variation	that	exists	between	HLA	matched	SCT	donors	
and	recipients.		10	From	these	data	it	is	possible	to	derive,	in	silico,	all	the	potential	alloreactive	
peptides	which	bind	the	relevant	HLA	(class	I	for	example)	in	a	donor-recipient-pair	(DRP),	and	in	
turn	this	metric	may	be	used	to	estimate	a	patient’s	given	potential	to	develop	alloreactivity,	or	
GVHD.		11	Aside	from	helping	understand	GVHD	pathophysiology,	this	library	of	recipient-derived	
mHA-HLA	complexes	may	also	be	used	to	interrogate	the	relationship	between	pathogen	
antigens,	as	well	as	tumor	antigens,	and	the	disease	states	that	may	result,	in	particular	the	
development	of	cross-reactive	illness,	such	as	GVHD	triggered	by	CMV	or	other	viral	
reactivation.		
T	cell	cross	reactivity	originally	was	uncovered	in	relation	to	autoimmunity,	especially	in	the	
context	of	CMV		12-15	and	solid	organ	transplantation.	16	TCR-peptide-HLA	class	I	bound	
complexes	exhibit	a	strong	recognition	of	2-4	central	amino	acid	residues	in	various	orientations	
and	allows	for	multiple	amino	acid	substitution	to	the	flanks	in	anchor	positions	while	relying	on	
HLA	and	peptide	sequences	simultaneously.	The	idea	of	T	cells	reacting	to	antigens	with	amino	
acid	sequence	homology	(≥6/6	consecutive	AA	residues	in	a	9-mer	for	example)	on	different	cell	
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types	with	a	given	HLA-class	I	type	has	taken	hold	from	multiple	clinical	examples.		13	Therefore,	
while	CMV	and	other	B-Herpesviruses	have	been	shown	to	be	associated	with	autoimmunity	
and	contribute	to	oncogenic	progression	possibly	affecting	relapse	rates,		17	CMV-specific	T	cell	
cross	reactivity	through	adoptive	lymphocyte	transfer	has	been	shown	effective	in	the	
treatment	of	glioblastoma	multiforme	upon	reactivation.		18,19	These	clinical	trials	centering	on	
confirmed	CMV-specific	T	cell	cross	reactivity	with	infected	tumor	cells	highlights	the	
expectation	of	eliciting	an	immune	response	to	CMV	and	‘self’	tumor	cells	simultaneously.	
However,	the	development	of	CMV-specific	T	cells	in	that	manner	raises	the	question	of	eliciting	
a	cross-reactive	GVHD	response	against	HLA	bound-alloreactive	recipient	peptides.	In	theory,	
this	will	occur	due	to	peptide	polymorphisms,	resulting	from	single	nucleotide	polymorphisms	
(SNPs),	identified	in	the	recipient	that	may	mimic	CMV	peptides	(or	vice	versa	)	with	enough	
sequence	homology	to	elicit	strong	HLA-specific	immune	responses,	and	presented	as	targets	to	
donor	lymphocytes	(Figure	1).	
Therefore,	if	CMV-derived	HLA	class	I	bound	oligopeptide	have	sequence	homology	with	human,	
alloreactive	peptides	bound	to	the	same	HLA	class	I	and	trigger	cross	recognition	by	donor	T	
cells,	the	presence	of	these	cross-reactive	peptides	may	constitute	a	risk	factor	for	the	
development	of	GVHD	following	SCT.	In	this	study,	HLA	bound	peptide-match	analysis	is	
facilitated	by	a	newly	compiled	Human	CMV	CROSS	(Cross-Reactivity	Open	Source	Sequence)	
database.	There	were	significant	total	CMV	proteomic	matches	present,	and	in	a	majority	of	
CMV	sero-positive	patients	with	GVHD,	this	was	corroborated	by	GVHD-specific	organ	incidence	
of	the	human	peptide	source	genes.	These	findings	suggest	that	there	may	exist	a	potential	
CMV-Human	polymorphic	peptide	influence	or	trigger,	supporting	a	link	between	CMV	
reactivation	and	GVHD		8.		
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Methods	
Whole	Exome	Sequencing	and	Peptide	Library	Creation	
Patients	with	recurrent	or	high-risk	hematological	malignancies	undergoing	allogeneic	SCT	at	
Virginia	Commonwealth	University	were	included	in	this	retrospective	study	following	
Institutional	Review	Board	approval.	Previously	cryopreserved	DNA	samples,	de-identified	by	
clinical	research	staff,	were	whole	exome	sequenced.	These	recipients	received	an	allograft	
from	either	a	related	or	an	unrelated,	HLA-matched	donor.	Initially,	9	DRPs,	including	4	HLA-
matched	related	(MRD)	and	5	unrelated	(MUD)	donor	recipients,	were	annotated	for	
identification	of	all	the	non-synonymous	single	nucleotide	polymorphisms	(nsSNPs),	across	the	
whole	exome,	in	the	graft	versus	host	(GVH)	direction	(nsSNP(GVH)),	i.e.,	polymorphism	present	
in	the	recipient	but	absent	in	the	donor.		10	Each	nsSNP(GVH)	was	analyzed	using	the	ANNOVAR	
software,		20	as	previously	described,		11	to	populate	the	flanking	amino	acids	around	each	amino	
acid	coded	for	by	each	of	the	polymorphisms.	This	was	accomplished	through	sequence	
padding,	using	DB	SNP130	and	hg18	genome	coordinates,	and	yielded	17-mer	peptides	with	
variant	amino	acids	occupying	the	central	location.	This	17-mer	oligopeptide	library	created	the	
opportunity	to	derive	9	separate	9-mer	recipient	oligopeptides,	using	a	sliding	window	method,	
with	the	polymorphism-derived	amino	acid	positioned	at	position	1-9	from	C-	to	N-terminus.	
The	nine	oligopeptides	generated	per	nsSNP(GVH)	were	extended	to	the	whole	exome	for	each	
recipient,	representing	each	DRPs’	unique	peptide	library.	Subsequently,	the	number	of	DRPs	
analyzed	was	expanded	to	77,	with	donor	and	recipient	samples	undergoing	whole	exome	
sequencing	and	peptide	library	generation.	
In	Silico	Peptide-HLA	Binding	Affinity	Determination	
Patient	peptide	libraries	were	initially	analyzed	by	the	NetMHCpan	software,	version	2.8.	21,22	
The	analytic	output	yielded	source	gene	information,	polymorphic	peptide	sequence	(9-mer),	
and	a	calculated	IC50	value	from	the	NetMHCpan	algorithms	for	each	of	the	six	HLA	class	I	
molecules,	HLA-A,	B	and	C	in	each	DRP.	IC50	values	(nM)	indicated	the	amount	of	peptide	
required	to	displace	50%	of	intended	or	standard	peptides	specific	to	a	given	HLA.	Binding	
affinity	is	inversely	related	to	IC50	values	such	that	a	smaller	IC50	value	indicated	a	stronger	
affinity.	The	variant	alloreactive	peptides	with	a	cutoff	value	of	IC50	≤500	nM	to	the	relevant	
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HLA	were	included,	and	designated,	presented	peptides;	and	those	that	had	an	IC50	≤50	nM,	
were	termed	strongly	presented	peptides.	IC50	values	in	this	range	(IC50<500	nM)	were	
considered	relevant	in	previous	studies	of	HLA-binding		23	and	predictive	mouse	models	of	CTL	
response	to	vaccinia	virus	epitopes.		24	Further	processing	and	interrogation	of	HLA	binding	in	
sliding	9-mer	windows	allowed	for	affinity	sorting	and	HLA-specific	separation	along	with	gene	
information.		
Determining	Sequence	Homology	Between	Human	And	CMV	Derived	HLA	Bound	Peptides			
The	bioinformatic	pipeline	utilized	to	interrogate	SCT	DRPs	for	HLA	bound	polymorphic	peptides	
derived	from	nsSNP(GVH)	in	each	DRP	was	extended	and	refined	to	interrogate	each	SCT	DRP	
for	relevant	HLA	class	I	bound	CMV	peptides.	The	binding	of	CMV-derived	peptides	to	specific	
HLA	Class	I	molecules	was	the	first	step	towards	determining	their	sequence	homology	with	
human	HLA	bound	peptides.	This	bioinformatic	pipeline	is	depicted	in	Figure	2.	The	initial	step	
was	compilation	of	the	Human	CMV-CROSS	(Cross-Reactivity	of	Open	Source	Sequences).	This	is	
a	database	of	289	hCMV	proteins	or	variants	representative	of	the	entire	known	multi-strain	
inclusive	(Towne,	Toledo	and	AD169)	hCMV	proteome	sourced	from	NCBI	(Appendix	A;	Protein	
variants	had	a	single	or	multiple	amino	acid	difference	reported	for	the	same	protein/CMV	
gene;	Deduplication	was	performed	to	remove	bias).		25	The	next	step	was	the	utilization	of	
previously	created	patient	polymorphic	peptide	libraries	(derived	from	nsSNP(GVH)	in	each	DRP)	
for	initial	feasibility	of	BLAST	protein	sequence	alignment	analysis.		26	This	was	followed	by	a	
subsequent	confirmatory	CMV-Human	sequence	homology	analysis.	Sequence	homology	relied	
on	a	match	of	6	or	more	continuous	amino	acids	in	a	string	of	9	total	amino	acids	(6/6-9/9)	by	
sliding	window	analysis	to	identify	sequence	overlap	between	HLA	bound	9-mer	alloreactive	
human	and	hCMV	peptides.	Next,	HLA	Class	I	binding	prediction	(NetMHCpan)	was	performed	
for	the	hCMV	peptides,	screening	the	generated	hCMV	9-mer	peptides	for	HLA	binding	affinity	
across	the	test	patient	population	(n=9).		
A	specific	streamlined	bioinformatics	application	(Table	1)	was	developed	to	directly	compare	
the	alloreactive	donor-recipient	peptide	libraries	for	all	the	patients	(n=77)	to	the	HLA	bound	
hCMV	peptides	by	sequence	homology;	eliminating	the	need	for	the	Protein	BLAST	sequence	
alignment	(≥6/6	match	by	9-mer	sliding	window	analysis	using	all	9-mers	extracted	from	each	
database,	DRP	peptide	library	or	Human	CMV	CROSS	proteome,	pre-	binding	affinity	screening).	
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Binding	affinity	was	predicted	(NetMHCpan)	for	all	the	70,686	hCMV	9-mer	peptides	(resulting	
from	the	289	hCMV	proteins)	to	the	known	2,915	human	HLA-class	I	types	along	with	collection	
of	source	gene	information	(hCMV	and	Human	geneids),	which	were	used	to	sort	the	peptides	
for	strength	of	binding	affinity.	Immunogenicity	screening	was	then	performed	to	validate	CMV-
human	matched	peptides	for	the	presence	of	hCMV	gene	products	previously	reported	as	CD8+	
T	cell	targets	known	to	elicit	specific	immune	responses.		27	
Tissue	distribution	of	cross	reactive	peptides	
Homologous	CMV-Human	peptide	libraries	were	compiled	for	each	DRP	and	the	source	genes	
organized	for	putative	GVHD	target	tissue-specific	distribution	analysis	using	the	GTEx	portal	for	
expression	data.		28	Each	patient	with	GVHD	involving	specific	tissues	(e.g.,	skin)	had	tabulation	
of	those	disease-incident	tissue-specific	alloreactive	peptides	presented	by	their	HLA	(e.g.,	10	
skin	peptides	from	8	genes	expressed	in	the	skin)	and	the	remainder	GVHD	tissue	
peptides/genes	were	tabulated	as	other	or	nonspecific	to	the	patient’s	disease	then	tallied.	
Following	criteria	were	used	to	assign	CMV-Human	peptide	cross-reactivity	potential:	1.	Amino	
acid	sequence	homology	of	6/6	to	9/9	(9-mers)	between	CMV	and	Human	HLA	bound	peptides	
2.	IC50	values	less	Than	500	nM	for	binding	to	the	unique	HLA	in	each	DRP	(Presented	or	
strongly	presented	peptides)	3.	Human	Gene-GVHD	Tissue	Expression	Connection	(Patient	
specific,	i.e.	skin,	GI,	etc.)		
Patients		
CMV	reactivation	defined	as	≥250	copies	of	hCMV	DNA/μL	of	plasma	was	determined	by	PCR.	
Absolute	lymphocyte	counts	were	measured	at	least	twice	weekly	following	SCT	during	the	first	
100	days	and	at	least	once	weekly	out	to	6	months	following	SCT.	Human	CMV	titers,	
lymphocyte	counts	and	serum	immunosuppressant	drug	levels	were	collected	to	one	year	post	
SCT	from	patient	electronic	medical	records.	Acute	and	chronic	GVHD	was	diagnosed	according	
to	standard	clinical	criteria.	Student’s	T	test	was	utilized	for	statistical	analysis.			
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Results	
Patient	Characteristics	
Seventy-seven	DRPs	underwent	exome	sequencing	following	SCT,	and	were	assessed	by	
in	silico	analysis	for	alloreactivity	potential	derived	from	non-synonymous	SNPs	in	the	GVHD	
direction	as	previously	described.		11	The	cohort	comprised	of	27	MRD	and	50	MUD	SCT	
recipients	underwent	data	collection	for	retrospective	analysis	including	GVHD	occurrence	and	
hCMV	reactivation	information	(Supplementary	Table	1).	Of	the	30	patients	that	experienced	
hCMV	viremia	within	a	median	of	29	days	from	transplant,	26	were	hCMV-seropositive	or	
reactivated;	one	patient	had	drug-refractory	hCMV	infection,	and	succumbed	to	it.	CMV	
reactivation	was	experienced	in	conjunction	with	GVHD	in	18	of	the	30	patients,	13	of	whom	
experienced	hCMV	reactivation	prior	to	GVHD	onset.	Multiple	recurrences	of	hCMV	viremia	
were	experienced	in	11	of	the	30	patients	(2	or	more	separate	reactivation	events,	≥250	copies	
of	hCMV	DNA/μL	blood	per	event).		
CMV	-	Human	HLA	bound	peptide	homology	
Based	on	the	hypothesis	that	significant	amino	acid	sequence	homology	between	human-	and	
viral-derived	peptides	presented	on	the	same	Class	I	HLA	molecules	may	lead	to	donor	CD8+	T	
cell	cross	reactivity,	a	bioinformatic	pipeline	was	utilized	to	assess	sequence	homology	between	
the	patient’s	putative	alloreactive	peptide	library,	and	hCMV-derived	oligopeptides	bound	to	
each	recipient’s	HLA.	Whole	exome	sequencing	of	HLA	matched	SCT	donors	and	recipients	
revealed	2,463	±	603	nsSNPs	(mean±SD)	with	a	GVH	direction	per	MRD	and	4,287	±	1154	nsSNPs	
per	MUD	recipient	(Student’s	T-test,	p<0.001).	Following	ANNOVAR	9-mer	peptide	
determination	and	completion	of	the	sliding	window	analysis	of	the	resulting	17	amino	acid	
variant	oligopeptide	resulting	from	each	nsSNP,	43,705	±	10,938	nonameric	potentially	
alloreactive	human	peptides	were	identified	per	MRD	recipient,	and	77,025	±	21,170	per	MUD	
recipient.	These	were	organized	into	a	library	by	HLA-specific	binding	affinity	(IC50:	0-50,000	
nM).	Next,	each	alloreactive	Human	9-mer	peptide	library	was	further	evaluated	for	their	
degree	of	match	with	the	70686	nonamer	peptides	derived	from	the	hCMV	proteome,	utilizing	
the	HLA-specific	algorithmic	CROSS	database.	This	comparison	determined	sequence	homology	
for	strings	of	≥6/6	consecutive	amino	acids	between	the	two	sets	of	Human	and	hCMV	peptides,	
and	was	termed	‘sliding	window-match	analysis’.	This	initial	screen	yielded	an	average	of	29,659	
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±	9039	total	peptide	matches	per	MRD	patient	and	52,910	±	16122	total	peptide	matches	per	
MUD	patient	to	the	hCMV	proteome	(Student’s	T-test,	p<0.001)	following	analysis.	The	program	
output	reported	for	each	peptide	match,	the	geneid’s,	the	HLA,	IC50	values	(Range:	0-50,000	
nM)	and	complete	peptide	sequence,	as	well	as	the	shared	partial	peptide	for	degree	of	
sequence	homology.		
Upon	confirmation	that	all	77	patient	alloreactive	peptide-HLA	libraries	studied	had	matches	
with	the	hCMV	peptide-HLA	arrays,	the	degree	of	sequence	homology	in	tightly	HLA	bound	
peptides	(IC50:	0.01-500	nM)	was	determined.	Following	removal	of	duplicate	peptide	
sequences,	the	total	CMV-human	match	(homology)	library,	yielded	an	average	of	33	peptide	
matches	per	MRD	patient	and	44	peptide	matches	per	MUD	patient	(Student’s	T-test,	p=0.09),	
constituting	approximately	1%	of	the	total	matches	reported	(Table	2).	The	homologous	
sequence	information	per	patient’s	peptide	library	following	high	affinity	match	analysis	
(IC50<500)	was	compiled	into	Appendix	B;	this	includes	an	immunogenicity	sorting	performed	
for	hCMV	reactivating	patients.	Considering	the	degree	of	sequence	homology	present	between	
hCMV	and	human	peptides	bound	to	HLA	class	I	molecules	in	specific	DRP,	each	MRD	DRP	on	
average	had	31,	2,	0	and	0	relevant	nonameric	CMV-Human	peptide	matches	with	6/6,	7/7,	8/8	
and	9/9	sequence	homology	respectively	(Table	2).	Also	each	MUD	DRP	on	average	had	40,	3,	1,	
and	0	peptide	matches	with	6/6	-	9/9	sequence	homology	respectively.	As	expected	from	the	
donor	type	SNP	differences,	relevant	alloreactive	peptide	differences,	and	total	peptide	matches	
with	hCMV,	MUD	DRPs	exhibited	a	trend	for	a	higher	number	of	hCMV	matched	peptides	than	
MRD	DRPs	by	peptide	sequence	homology	differences	(6/6-9/9	matching;	student’s	T-test,	
p=0.07-0.38	respectively).	To	determine	the	correlation	of	the	number	of	high	affinity	CMV-
Human	matches	(IC50<500	nM)	with	sequence	homology	>6/6	amino	acids	in	76/77	patients,	
these	were	plotted	against	the	pool	of	total	alloreactive	peptides	per	patient	(Figure	3).	Notably,	
MUD	DRPs	post	screening	(IC50<500	nM)	exhibited	a	mean	of	6,545	±	2689	alloreactive	
peptides	per	patient	which	was	significantly	greater	than	the	4,522	±	1915	mean	alloreactive	
peptides	per	MRD	DRPs	(Student’s	T-test,	p<0.001)	prior	to	interrogating	for	matches	to	the	
hCMV	proteome,	with	a	trend	for	a	higher	prevalence	of	CMV-Human	matches	in	the	MUD	
recipients.	These	results	indicate	that	there	exists	a	pool	of	homologous-CMV-derived	peptides,	
which	may	be	presented	by	the	recipient	HLA	and	trigger	cross-reactive	donor	T	cell	
identification	of	recipient	alloreactive	peptides;	therefore	hCMV	reactivation	may	potentially	
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trigger	GVHD	in	some	patients.	These	data	also	identify	MUD	recipients	for	being	at	a	somewhat	
higher	risk	of	possible	alloreactivity	resulting	from	hCMV	reactivation.		
Potential	Immunogenecity	of	the	hCMV	Peptides	Presented	on	Recipient	HLA	
To	compare	the	sequence	homology	analysis	results	and	determine	the	presence	of	previously	
validated	immunogenic	hCMV	peptides,		27	the	specific	hCMV	peptide	sequences	and	the	
proteins	of	origin	were	reviewed	(Table	3).	Twelve	of	the	13	patients	with	hCMV	reactivation	
before	GVHD	onset	exhibited	one	or	more	immunogenic	hCMV	peptide	matches,	previously	
shown	to	elicit	a	hCMV-specific	T-cell	response	targeting	the	listed	source	genes.	The	remaining	
patient	expressed	CMV	–	Human	peptide-matches	specific	to	the	patient’s	affected	GVHD	
tissue,	which	had	not	previously	been	reported	in	other	studies.	The	analysis	revealed	multiple	
CMV-Human	peptide	matches	that	were	high	affinity	(IC50<500	nM),	immunogenic	and	
expressed	in	a	GVHD-affected	tissue-specific	manner.	Further,	the	binding	affinity	(reflected	by	
the	IC50	values)	of	hCMV	peptides	when	plotted	against	the	IC50	values	of	the	alloreactive	
Human	peptides	(Figure	4),	demonstrated	a	wide	range	of	values,	indicating	the	potential	for	
varying	degrees	of	cross	reactivity.	This	analysis	illustrates	the	magnitude	of	overlap	in	peptide	
sequence	between	the	two	sources	of	HLA	presented	peptides	and	provides	a	rational	
explanation	for	cross	reactivity	potentially	triggering	GVHD.		
Tissue	expression	of	cross-reactive	Human	peptides	
In	order	to	study	the	GVHD	tissue-specific	expression	of	the	hCMV	peptides	matched	to	human	
alloreactive	peptides	(Table	3),	gene	expression	data	organized	in	a	tissue	specific	manner	was	
obtained	from	the	GTEx	Portal	of	the	Broad	Institute	of	MIT	and	Harvard	(Version	6)		28.	Gene	
expression	data	for	all	CMV-Human	peptide	matches	in	the	30	hCMV	reactivating/de	novo	
infected	patients	was	compiled	(median	minimum	threshold	of	expression:	≥10	reads/kilobase	
of	transcript/million	mapped	reads),	specifically	focusing	on	GVHD	target	tissues	including:	skin,	
GI,	liver,	lung,	and	others	(vagina,	muscle,	adipose	and	salivary	gland).	A	focused	analysis	of	
GVHD	tissue	gene	expression	in	conjunction	with	actual	GVHD	occurrence	was	performed	on	18	
patients	with	GVHD	and	hCMV	reactivation,	and	showed	that	18/18	patients	had	expression	of	
hCMV-matched	alloreactive	peptides	(IC50<500	nM)	with	≥10	RPKM	tissue-specific	gene	
expression	(Table	4).	Combining	both	match	data	and	gene	expression	data,	a	cross	reactivity	
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profile	was	created	for	the	hCMV	infected	subset	of	patients	to	include:	match	number,	discrete	
numbers	of	peptides	(Human	and	CMV),	gene	count,	immunogenic	hCMV	genes,	and	tissue	
specific	GVHD	peptides	or	genes.	These	data	comprise	a	predictive	case	for	potential	
alloreactive	trigger	following	hCMV	infection	that	can	be	derived,	a	priori,	from	whole	exome	
sequencing	of	transplant	donors	and	recipients	using	this	analytic	approach.		
Clinical	correlations	
In	this	cohort	hCMV	reactivation	following	SCT,	was	associated	with	poorer	survival	(Log	Rank:	
4.5,	p=0.03,	Hazard	ratio:	2.31,	p=0.04)	when	adjusting	for	hCMV	reactivation	by	donor	or	
recipient	seropositivity	(Supplemental	Figure	1),	consistent	with	the	findings	of	a	recent	CIBMTR	
analysis		2.	To	determine	whether	there	was	any	association	between	onset	of	hCMV	
reactivation	and	GVHD,	we	evaluated	lymphocyte	growth	kinetics	and	large	variations	in	
calcineurin	inhibitor	levels	as	possible	triggers	of	GVHD	occurrence	in	the	above	referenced	
patients	(Table	4).	It	has	been	demonstrated	that	lymphocyte	recovery	after	SCT,	follows	logistic	
dynamics,	with	departures	from	the	logistic	curve	being	recorded	at	the	time	of	
infection/relapse	etc.	29	By	examining	case	studies	of	multiple	hCMV-reactivating	patients,	we	
observed	that	their	reactivation	events	were	at	times	coincident	with	GVHD	onset	and	often	
associated	with	preceding	lymphocytosis,	suggestive	of	an	alloreactive	cellular	immune	
response.	Acute	GVHD	onset	following	CMV	reactivation	was	present	in	7/13	hCMV	reactivation	
before	GVHD	patients;	acute	GVHD	alone	without	chronic	GVHD	indicated	poorer	outcome	in	
this	cohort	of	patients,	with	3	patients	experiencing	Grade	IV		GI	disease	(two	were	steroid	
refractory)	which	was	fatal	in	all	cases.	As	seen	in	figure	5A,	with	acute	GVHD	in	patients	47,	68,	
70,	there	was	evidence	of	hCMV	reactivation	events	(top	graph)	that	preceded	a	burst	of	
lymphocytosis	(middle	graph)	and	often	occurred	with	stable	CNI	or	immunosuppression	levels	
(bottom	graph),	indicating	a	potential	hCMV-GVHD	relationship.	Patients	47,	68	and	70	with	
Acute	GI	GVHD	had	an	average	of	20.3	±	9.3	matches	(±SD)	derived	from	18.7	±	7.8	human	
peptides.	Patient	68	also	exhibited	skin	and	liver	GVHD.	When	comparing	the	Acute	GVHD	
patients	to	Chronic	or	Acute	+	Chronic,	we	did	note	a	‘quality	over	quantity’	trend	emerging	
when	considering	the	percentage	of	genes	with	GVHD-specific	tissue	expression	on	average,	in	
these	3	patients	GI	tract	specific	alloreactive-hCMV	matched	genes	were	80.6	±	17.3	%.	Patients	
depicted	in	figure	5B	exhibited	the	more	stable	or	gradual	hCMV	reactivation	effects	seen	in	
chronic	GVHD	patients	10	and	27,	where	lower	or	less	frequent	spikes	in	hCMV	titers	may	still	
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elicit	lymphocyte	growth	just	at	a	more	controlled	rate,	probably	accounting	for	that	perceived	
difference	in	outcomes	between	patients	with	symptoms	of	only	acute	GVHD	or	chronic	GVHD.	
Patients	10	and	27	with	Chronic	Skin	GVHD	had	a	mean	of	68	±	5.7	matches	(±SD)	derived	from	
50.5	±	10.6	human	peptides.	These	two	patients	exhibited	a	lower	percentage	of	GVHD-tissue	
specific	gene	expression	on	average	when	considering	all	potential	GVHD	genes	identified,	in	
this	instance	skin	gene	expression	amounted	to	51.9	±	2.7%.		The	final	two	cases	(patients	71	
and	84,	Figure	5C)	exhibited	symptoms	of	both	acute	and	chronic	GVHD,	but	patient	84’s	lower	
grade	cyclical	reactivation	events	altered	the	lymphocyte	growth	pattern	towards	a	sinusoidal	
pattern.	Patients	71	and	84	exhibiting	both	acute	and	chronic	GVHD	had	a	mean	of	40	±	21.2	
matches	(±SD)	derived	from	25	±	5.7	human	peptides.	Patient	84	also	exhibited	GI	GVHD.	
Patient	71	was	de	novo	infected	and	continued	with	a	low-grade	infection	for	200+	days	prior	to	
declining	counts	towards	relapse.	Patients	71	and	84	also	exhibited	lower	GVHD-tissue	specific	
gene	expression	on	average	when	considering	all	potential	GVHD	genes	identified,	Skin	or	GI	
(primary	organs):	45.8	±	29.5%.		These	variable	dynamics	of	hCMV	reactivation	and	GVHD	onset	
demonstrate	the	complexity	involved	in	analyzing	the	relationship	between	ongoing	
immunosuppression	in	the	setting	of	multiple	sets	of	potentially	cross	reactive	antigens	by	
affected	organ	system	being	presented	to	a	reconstituting	donor-derived	immune	system.			
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Discussion	 	
CMV	reactivation	is	a	frequent	complication	of	allografting,	requiring	frequent	monitoring	and	
associated	with	an	increased	risk	of	treatment	related	mortality,	primarily	in	its	own	right,	but	
also	because	it	is	frequently	associated	with	GVHD.		8	Therapy	and	effective	prophylaxis	involve	
the	use	of	toxic	drugs	and	monitoring	for	reactivation	is	not	straightforward.	The	ability	to	
identify	patients	at	risk	of	developing	alloreactive	complications	from	hCMV	reactivation	will	
therefore	be	a	useful	adjunct	to	the	supportive	care	of	transplant	recipients,	as	well	as	an	
important	step	forward	in	understanding	virus	induced	alloreactivity.		In	this	paper	a	
computational	algorithm	that	identifies	hCMV	peptides	homologous	to	human	alloreactive	
peptides	is	described.	This	determination	required	three	steps,	whole	exome	sequencing	of	
transplant	donors	and	recipients,	followed	by	in	silico	determination	of	the	patient	specific	class	
I	HLA	binding	of	the	oligopeptides	resulting	from	the	nsSNP	in	the	exome	and	finally	a	
comparison	of	these	alloreactive	peptide	sequences	with	those	of	hCMV	peptides	predicted	to	
bind	the	same	HLA	molecules.	This	algorithm	identifies	a	number	of	hCMV	peptides	which	bind	
the	same	HLA	as	human	alloreactive	peptides	with	a	similar	range	of	binding	affinities	and	may	
potentially	be	cross	presented	to	donor	T	cells.		
To	understand	how	this	may	impact	GVHD	pathophysiology,	consider	a	T	cell	clone	(TCCMV)	
which	recognizes	these	hCMV	peptide-HLA	complexes,	is	activated	by	a	hCMV	viremia.	The	T	cell	
receptor	of	this	clone	may	also	recognize	a	human	alloreactive	peptide	with	sequence	homology	
to	the	hCMV	peptide	and	bound	to	the	same	HLA	molecule.	Even	if	it	does	so	weakly,	tissue	
damage	may	be	initiated	and	GVHD	ensue.	This	process	can	work	in	reverse	as	well,	a	T	cell	
clone	with	high	affinity	for	alloreactive	peptides	(TCmHA)	,	which	only	binds	the	hCMV	peptide-
HLA	complex	weakly	may	be	‘set-off’	by	a	hCMV	reactivation	event,	again	leading	to	down	
stream	GVHD.	This	general	principle	likely	holds	true	for	most	viruses.		
	 	 TC	CMV		 	 					CMVp-HLA		 	 	 	 	 	 	 	
	 	 	 	 						mHA-HLA	 	 TC	mHA	
A	mathematical	model	utilizing	matrices	has	been	developed	to	understand	aggregate	T	cell	
responses	to	many	mHA-HLA	complexes	the	donor	T	cells	may	encounter	in	the	recipient	milieu.		
30	The	simplifying	notion	underlying	this	model	is	that	each	T	cell	interacts	with	a	single	antigen,	
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therefore	an	identity	matrix	may	be	used	to	calculate	the	resulting	T	cell	response.		This	model	
requires	that	the	antigens	occupy	the	matrix	operator	(MAPO)	and	T	cell	vector	gets	transformed	
by	the	operator,	as	seen	in	the	matrix	below.				
SCT	 𝕄!"#	
𝜈!"#	↓ t	𝜈!"# 	
	 mHA1	HLA	 mHA2	HLA	 mHA3	HLA	 mHAn	HLA	
TC1	 1	 0	 0	 0	
TC2	 0	 1	 0	 0	
TC3	 0	 0	 1	 0	
TCn	 0	 0	 0	 1	
In	the	above	simplified	matrix	T	cell	clone,	TC1	only	interacts	with	mHA1,	and	so	on.	The	1	in	the	
cells	means	that	the	T	cells	recognize	that	antigen	and	responds,	and	0	means	absence	of	
recognition.	In	reality,	the	TCR-Ag-HLA	interactions	are	not	likely	to	be	quite	so	simple.	An	
important	clue	to	this	is	the	observation	that	antigen-HLA	binding	as	indicated	by	IC50	does	not	
occupy	discrete	states	of	0	or	1	(binding	or	no	binding);	instead	there	is	a	continuum	of	IC50	
values.	So	in	the	case	of	cross-reactive	antigens,	a	hCMV	derived	antigen	binds	the	same	HLA	
molecule	and	interacts	with	the	T	cell	receptor,	albeit	with	a	different		binding	affinity.	This	
implies	that	each	TCR	might	interact	with	multiple	antigens	with	different	affinity,	thus	the	0	
gets	replaced	with	a	series	of	numbers	between	0	and	1.	These	cross-reactive	antigens	triggered	
by	weakly	interacting	antigens	may	augment	the	T	cell	response	to	the	target	antigens.			
SCT	 𝕄!"#	
𝜈!"#	↓ t	𝜈!"# 	
	
mHA1	HLA	
(CMVp1	HLA)	
mHA2	HLA	
(CMVp2	HLA)	
mHA3	HLA	
(CMVp3	HLA)	
mHAn	HLA	
(CMVpn	HLA)	
TC1	 1	 (0.2*)	 0	 0	
TC2	 0	 1	 (0.1*)	 0	
TC3	 (0.3*)	 0	 1	 (0.1*)	
TCn	 0	 0	 (0.5*)	 1	
	*	indicates	response	of	the	relevant	T	cell	clone	to	a	viral	pathogen	peptides,	bound	to	
the	same	HLA	as	the	mHA	and	recognized	by	the	same	T	cell	clone.		
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This	matrix	demonstrates	the	perspective	from	an	alloreactivity	operator,	however	if	one	were	
to	think	about	the	operator	constituting	a	hCMV	infected	tissue,	the	following	distribution	of	T	
cell	interactions	may	be	observed	
SCT	 𝕄!"#	
𝜈!"#	↓ t	𝜈!"# 	
	
CMVp1	HLA	
(mHA1	HLA)	
CMVp2	HLA	
(mHA2	HLA)	
CMVp3	HLA	
(mHA3	HLA)	
CMVpn	HLA	
(mHAn	HLA)	
TC1CMV	 (0.3*)	 1	 0	 0	
TC2CMV	 0	 (0.2*)	 (0.1*)	 0	
TC3CMV	 1	 0	 (0.5*)	 1	
TCnCMV	 0	 0	 1	 (0.1*)	
*	indicates	alloreactive	mHA,	bound	to	the	same	HLA	as	the	viral	peptides	and	recognized	by	the	
a	different	set	of	T	cell	clones,	which	recognize	the	hCMV	peptide	as	the	primary	target	and	
have	the	mHA	as	a	target	with	cross	reactivity.	
Above	conceptual	explanation	aside,	clinical	correlation	indicates	that	patients	meeting	the	
previously	described	criteria	for	cross	reactivity,	experienced	hCMV	reactivation	and	subsequent	
GVHD	onset,	as	noted	in	the	sevral	case	studies	presented.	It	can	be	seen	that	hCMV	
reactivation	directly	preceding	lymphocytosis		was	found	in	a	subset	of	our	population	which	
may		indicate	an	autoimmune	like	relationship	based	on	genetic	predisposition	or	the	quality	of	
the	matching	peptides	bound	with	great	affinity	to	specific	HLA	with	appropriate	protein	
abundance	or	gene-tissue	expression	for	GVHD	to	occur.			
While	the	in	silico	analysis	for	hCMV	+	alloreactivity	potential	reveals	a	large	body	of	antigens	
which	may	influence	clinical	outcomes,	there	are	caveats	to	be	considered	in	developing	this	
peptide	analysis	pipeline.	First,	the	process	of	creating	the	CMV	CROSS	database	included	some	
variant	forms	of	the	hCMV	proteins	known	to	have	differing	amino	acid	lengths	that	may	allow	
for	duplicates,	which	were	accounted	for	during	multiple	processes	of	deduplication.	However	
the	slight	differences	to	the	variant	forms	of	the	proteins	reported	in	the	NCBI	database	may	
generate	a	few	more	peptide	possibilities	than	may	be	realistic	but	would	allow	for	strain	
differences	of	the	human	peptide	matches	during	exome	sequencing.	The	actual	process	of	
matching	peptides	or	component	sequences	(6/6-9/9)	also	allowed	for	multiple	match	
possibilities	by	slight	human	9-mer	sliding	window	changes	to	peptides,	multiple	matches	to	the	
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same	CMV	proteins	at	different	sites,	strings	of	repeated	amino	acids	(i.e.,	AAAAAA	or	SSSSSS)	
allowing	for	multiple	matches	or	limited	peptide	match	possibilities	from	terminal	amino	acid	
polymorphisms	on	various	proteins.	These	points	may	introduce	some	small	bias,	which	was	
accounted	for	by	removing	duplicate	matches	at	multiple	time	points	and	counting	genes	or	
peptides	discreetly	apart	from	the	number	of	matches,	which	may	be	inflated	in	the	described	
instances	above.	An	interesting	note	in	this	same	vein	was	observed	among	patient	or	hCMV	
peptides,	where	human	genes	and	hCMV	immunogenic	genes	were	shared	among	multiple	
patients	with	many	of	each	gene	or	peptide	involved	being	common	in	our	cohort,	often	with	
the	same	HLA	specificity	and	predicted	binding	affinity,	resolving	that	there	is	likely	still	a	more	
complex	pattern	to	unravel	from	this	approach	to	cross-reactivity	potential	(Appendix	B).	
Epitope	spreading	is	another	phenomenon,	in	stem	cell	transplant	similar	to	autoimmune	
disorders,	that	would	be	exemplified	by	donor	lymphocytes	and	antigen	presenting	cells	
encountering	either	hCMV	or	recipient	alloreactive	peptides	released	upon	organ	damage	that	
may	be	processed	and	presented	on	restricted	HLA	with	enough	sequence	homology	to	their	
ligands,	hCMV	or	alloreactive	peptides,	to	elicit	an	immune	response.	Also	an	inherent	genomic	
similarity	might	be	expected	over	a	long	course	of	coevolution	due	to	viral	latency	where	hCMV	
has	adopted	our	genetic	information	for	immune	evasion	in	the	majority	of	the	population	by	
molecular	mimicry.		
CMV	has	evolved	in	parallel	with	the	human	genome	over	hundreds	of	millions	of	years,	
potentially	exchanging	genetic	information	from	virus	and	human	randomly	with	each	latent	
infection,	selecting	primarily	for	immune	evasion.	Human	CMV	has	adopted	many	well-known	
immune	evasive	strategies	but	employing	human	peptides	for	the	purpose	of	molecular	
mimicry,	including	the	production	of	decoy	HLA-peptide	complexes	or	immunosuppressive	viral	
IL10,	has	proven	to	be	one	of	the	most	successful	strategies.		31	This	molecular	mimicry	shields	
hCMV	from	a	portion	of	the	immune	response	but	also	exposes	endogenous	antigens	from	
recipient	cells	simultaneously	with	hCMV	antigens	to	donor	immune	surveillance	during	organ	
damage	from	lytic	reactivation	in	athymic	adults.		32	This	form	of	epitope	spreading,	developing	T	
cell	antigenic	experience,	affects	overall	immune	responses	and	may	account	for	the	robust	
CD8+	T	cell	response	to	hCMV	infection	in	otherwise	healthy	individuals	(10%	of	the	entire	T	cell	
compartment)	that	inflates	with	age.		27		In	addition,	the	primarily	memory	T	cell	response	to	
hCMV	accounts	for	the	sharp	responses	to	various	hCMV	antigens	upon	reactivation,	which	may	
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be	as	great	as	50	fold	the	strength	of	a	naïve	T	cell	response	during	primary	infection.		15	Prior	
evidence	of	eliciting	a	strong	CD8+	and	CD4+	response	to	soluble	recombinant	hCMV	antigen,	
measured	by	IFN-gamma	production,		33	indicates	the	presence	of	epitope	spreading	in	the	
realm	of	post-transplant	viral	immunity	as	it	has	already	been	discovered	in	Multiple	Sclerosis	
and	implicated	in	other	autoimmune	disorders.		17,34,35	
When	considering	the	opportunity	for	hCMV	to	catalytically	trigger	GVHD	apart	from	the	
potential	method	we	propose	here,	we	must	first	note	that	hCMV	is	the	largest	of	the	
herpesvirus	family	with	a	235	kb	DNA	genome	capable	of	encoding	more	than	200	potential	
protein	products	36	and	second	the	near	ubiquity	of	cells	it	is	capable	of	infecting	in	man,	
including	parenchymal	and	connective	tissue	cells	of	virtually	any	organ	along	with	various	
hematopoietic	cell	types	(epithelial,	endothelial	-	including	vascular	and	each	organ,	fibroblasts,	
smooth	muscle	cells,	monocytes	and	macrophages).		37	Most	chronic	human	viral	genomes	
experienced	in	the	SCT	population	are	much	smaller	in	size,	e.g.	adenovirus	26-45	kb,		38	BK	virus	
and	JC	virus	are	approximately	5	kb	39	and	most	respiratory	viruses	<20	kb,		40,41	indicating	a	
much	greater	potential	peptide	pool	for	hCMV	to	draw	from	for	purposes	of	molecular	mimicry	
and	immune	evasion.	The	potential	for	hCMV	infection	in	nearly	any	cell	type	obviates	the	noted	
wide	scale	CD8+	T	cell	expansion	that	occurs	upon	reactivation	but	also	the	potential	for	epitope	
spreading	upon	organ	damage	throughout	the	human	body,	especially	the	large	surface	area	
tissues	with	immune	exposure	like	the	vasculature,	skin,	gastrointestinal	tract,	liver	and	lungs.	
When	we	compare	hCMV	to	the	other	herpesviruses	on	tissue	specificity,	HHV6	infects	a	slightly	
more	restricted	variety	of	human	cells	but	prefers	replication	in	vitro	in	CD4+	T	cells	which	HHV7	
infects	primarily,		42,	EBV	infects	B	cells	or	epithelial	cells	43	and	HSV	(150	kb)	can	infect	many	
cells	while	its	latency	is	neuron	restricted.	44	Thus,	hCMV	seems	uniquely	well	suited	to	have	a	
high	potential	for	molecular	mimicry	as	well	as	its	presence	in	the	vasculature	and	epithelium	of	
almost	every	organ.		
In	conclusion,	this	paper	reports	sequence	homology	in	HLA	bound	peptide	antigens	of	hCMV	
and	human	origin.	Given	the	distribution	of	human	peptides	in	various	tissues,	and	their	
involvement	with	GVHD	in	the	patients	examined,	we	posit	that	hCMV	derived	peptides	may	
influence	the	development	of	GVHD	in	patients	who	develop	hCMV	reactivation	following	SCT.	
These	findings	support	the	use	of	more	aggressive	antiviral	strategies	for	preventing	hCMV	
reactivation	in	patients	undergoing	allografting	and	argue	against	the	use	of	simply	monitoring	
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as	the	major	therapeutic	strategy.	We	endeavor	in	the	future	to	understand	the	supporting	
CD4+	T	cell	hCMV	protective	dynamics	involved	by	interrogating	HLA	class	II	peptides,	1	looking	
at	potential	influences	of	human	CMV	mimicry	and	unraveling	the	potential	GVHD/CMV	cross-
reactivity/Auto-immune	relationship	further		9,14,17,45-49.	
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Tables.		
Table	1.	Match	Algorithm	&	Analytic	Design.			
	
Table 1. HCMV	cross-reactivity	potential	of	77	SCT	DRP	from	whole	exome	sequencing	data	using	sliding	window	match	analysis
1   289 HCMV protein sequences representative of the HCMV proteome were downloaded from NCBI by batchentrez utility
2   Downloaded CMV protein sequences were sliced into 9AA peptides and deduplicated, resulting in a library of 70686 9AA peptides
3   Each of the 70686 9AA peptides were further divided into 2 8AA, 3 7AA and 4 6AA peptides to form a lookup table for 
     each component peptide (6,7,8) with the one or more 9AA parent peptide(s) and the associated CMV geneid
4   As a focus on Class I HLA, a list of the 2915 plausible HLA-A/B/C types interrogated by netmhcpan was compiled
5   IC50 values for all 70686 9AA CMV peptides were precalculated against all 2915 HLA types and saved in the CROSS database 
6   9-mer peptides isolated from ANNOVAR per patient were searched for match with the 9AA CMV peptide pool
     … if no match found then each 9-mer was split into 2 8-mers and each searched in the 8AA CMV peptide pool
     … if still no match found then each 9-mer was split into 3 7-mers and each searched in the 7AA CMV peptide pool
     … if still no match found then each 9-mer was split into 4 6-mers and each searched in the 6AA CMV peptide pool
7   If any of  the above searches found a match, the search was terminated and results for that patient 9-mer peptide reported
8   Reported 9-mers were linked with geneid (Human & CMV), HLA type, IC50 (Human & CMV), partial peptide (6/7/8), CMV_peptide (9)
9  Each patient-specific peptide library generated by comparing alloreactive peptides with the CROSS database were compiled, 
    statistically analyzed (Student's T-Test) and further screened for high affinity binding (1/IC50 or an IC50 range of 0-500 nM)
10  Binding strength (IC50<500 nM) of homologous CMV and human peptides to DRP-specific HLA was compared for pattern analysis
13  Gene Tissue Expression (GTEx) data was gathered on CMV infected patients (n=30) to find GVHD specific organ incidence
14  Case studies were prepared, 7 patients with CMV before GVHD: 3 acute GVHD, 2 chronic GVHD and 2 aGVHD + cGVHD.
11 Immunogenicity of common CMV gene products as CD8+ T cell targets was screened for validation on CMV infected patients (n=30)
12  CMV peptide matches to Human alloreactive peptides underwent multiple rounds of deduplication to ensure only unique peptide 
      inclusion by both software programming (Excel or independent coding) and finally by human observation upon final analysis.
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Table	2.	CMV-	Human	match	analysis	per	DRP	(IC50	<500	nM)	by	donor	type	according	to	
continuous	amino	acid	sequence	homology	(one	standard	deviation	from	the	mean	value)	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Mean	Relevant	
Matches	(IC50<500)
Number	of	
Patients	(n)
Sequence	
Homology	
6/6	(±SD)
Sequence	
Homology	
7/7	(±SD)
Sequence	
Homology	8/8	
(±SD)
Sequence	Homology	
9/9		(±SD)
Total	6/6	
to	9/9		
(±SD)
MRD 27 31	±	19 2	±	2 0	±	1 0	±	0 33	±	20
MUD 50 40	±		33 3	±	6 1	±	2 0	±	1 44	±	39
Overall 77 37	±	29 3	±	5 1	±	2 0	±	1 40	±	34
Student's	T-test	(p<.05) 0.12 0.09 0.07 0.38 0.09
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Table	3.	GVHD	tissue-specific	immunogenic	CMV	peptide	matches,	CMV	reactivation	before	
GVHD	patients.	Patient-specific	process	of	cross	comparison	along	with	the	source	genes,	IC50	
values	to	indicate	inverse	binding	affinity	and	GVHD	organ	specific	tissue	involvement.	
	
Note:	Twelve	patients	with	CMV	reactivation/infection	before	GVHD	onset	exhibited	previously	identified	
immunogenic	CMV	peptide	matches	with	gene	expression	specific	to	the	tissues	affected	by	GVHD	
(above);	The	filter	of	immunogenicity	provides	a	connection	to	T	cell	reactivity	shown	in	vitro	to	the	listed	
CMV	genes	in	a	separate	patient	population;	Patient	79	with	muscle/fascia	GVHD	showed	no	muscle-
specific	previously	known	immunogenic	CMV	peptide	matches	but	still	had	three	relevant	CMV	peptide	
matches	expressed	in	the	skeletal	muscle	(not	shown);	Tissues	in	parentheses	were	also	affected	by	GVHD	
but	without	immunogenic	matches/expression	by	patient;	Patients	67	and	71	experienced	de	novo	CMV	
infection.	 	
Patient HLA Human	Gene IC50	Value DRP	Peptide CMV	Peptide IC50	Value CMV	Gene
GVHD	Organ	with	
Target	Gene	Expression
10 HLA-B40:01 TSPYL1 11.67 SETVALPPL QENSETVAL 23.37 UL86 Skin
HLA-B40:01 HDAC7 26.71 EEVEAVTAL AEREAVTAL 19.95 UL49
HLA-B08:01 APEH 486.52 NRRSALYSV MWKNRRSAL 10.53 UL37
HLA-B08:01 WKNRRSALL 273.97 UL37
27 HLA-C03:04 IL22RA1 15.86 IVHPTPTPL SSTPTPTPL 41.56 UL82 Skin
HLA-A02:01 TECR 28.47 ALFSLVVFT YLFSLVVLV 2.76 US3
HLA-A02:01 LVYLFSLVV 441.74 US3
HLA-C03:04 WNK1 41.43 ITAAATAPV TTAAATATV 198.72 UL105
45 HLA-A68:02 PPP1R15A 149.06 SSAAAAAAL TAAAAAAAA 57.77 IRS1,TRS1 Skin	&	Vagina
HLA-A68:02 ATAAAAAAA 59.30 IRS1,TRS1
HLA-A68:02 DAAAAAAPT 285.57 IRS1
HLA-A68:02 SVSSSAAAA 376.07 UL105
HLA-A68:02 SASAAAAAA 468.89 UL105
HLA-A68:02 DATAAAAAA 469.93 IRS1,TRS1
HLA-A68:02 MUC21 106.17 ESSTTSSGA TTYTTSSGA 23.86 UL86 Vagina
HLA-A68:02 YTTSSGAKI 139.73 UL86
HLA-A68:02 HOXD13 351.91 AAAAAAAGA TAAAAAAAA 57.77 IRS1,TRS1
HLA-A68:02 ATAAAAAAA 59.30 IRS1,TRS1
HLA-A68:02 DAAAAAAPT 285.57 IRS1
HLA-A68:02 SASAAAAAA 468.89 UL105
HLA-A68:02 DATAAAAAA 469.93 IRS1,TRS1
47 HLA-B07:05 MUC17 52.25 TPVSHTLVA TPVSHTQPL 7.58 UL150 GI
HLA-A30:02 CARS2 342.62 SPASLSSLY YFDSLSSLY 173.23 UL29,UL28
48 HLA-A31:01 PLXND1 200.40 LFVFCTKSR NLFVFCTER 57.60 UL34 GI	(Skin	&	Liver)
HLA-A31:01 PLXND1 307.31 VALFVFCTK
67 HLA-A02:01 FGFR4 19.97 RLLLALLGV VLLLALLLL 208.77 US29 GI,	Lung	(Skin)
HLA-A02:01 FGFR4 164.97 LLLALLGVL
68 HLA-A31:01 ALCAM 187.60 TYTLTAVRR ASLLTAVRR 68.25 IRS1,TRS1 GI,	Liver	(Skin)
70 HLA-C07:02 LCN2 121.85 SYPGLPSYL MRPGLPSYL 49.96 UL75 GI	
HLA-B35:01 SERPINB4 97.29 EAAAATAVL CAAAAATAA 393.01 UL105
HLA-A03:01 FYCO1 488.05 RASLKRLVK STLKRLVKK 83.46 UL69
71 HLA-C03:03 PPP1R15A 19.38 SSAAAAAAL AAAAAAPTV 48.37 IRS1,TRS1 Skin
HLA-C03:03 AAAAAAAAA 343.39 IRS1,TRS1
HLA-C03:03 TAAAAAAAA 388.91 IRS1,TRS1
HLA-C03:03 SASAAAAAA 421.08 UL105
HLA-A30:02 CARS2 342.62 SPASLSSLY YFDSLSSLY 173.23 UL29,UL28
76 HLA-A03:01 ZZEF1 119.19 SVLSELLKK SVLSELLNK 90.92 UL54 GI
HLA-B27:05 MUC4 414.06 TRHATSLPV YQLRHATSL 473.18 US29
90 HLA-A02:01 PELP1 77.94 LLALLLAPT LLALLLLEL 37.59 US29 Skin	&	GI
HLA-A02:01 VLLLALLLL 208.77 US29
HLA-A02:01 AHSA1 321.16 KTLFLAVQV ELFLAVQFV 144.94 UL86
HLA-C03:03 TCF7L1 106.99 AAASSSGQM AAASSSSAV 26.73 UL48 GI
HLA-C03:03 IAAASSSSA 219.78 UL48
HLA-A03:02 ZZEF1 325.00 SVLSELLKK SVLSELLNK 184.87 UL54
HLA-C03:03 PLEKHA6 384.99 AASSSLRRL FGGAASSSL 71.10 UL122
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Table	4.	Human-CMV	short	sequence	homology	in	GVHD	Tissue	Specific	Peptide	and	Gene	
Distribution	from	GTEx	Analysis	(n=18).	GVHD	incidence	denotes	the	specific	organs	affected	in	
each	patient;	Peptides,	lists	the	number	of	unique	peptide-HLA	complexes	matched	between	
human	and	CMV	peptide	library;	the	column,	Genes	lists	the	source	genes	for	the	afore	
mentioned	peptides;	GVHD	tissue	specific	peptides	lists	the	number	of	peptides	which	bind	HLA	
with	an	IC50	<500nM,	and	are	expressed	in	tissues	affected	by	GVHD;	GVHD	tissue	gene	
expression	denotes	the	number	of	genes	expressed	at	an	RPKM	>10	corresponding	to	the	GVHD	
tissue	specific	peptides.	
	
	
	
Note:	*-	All	patients	with	an	asterisk	following	their	numeric	representation	experienced	CMV	
reactivation	prior	to	GVHD	(except	Patients	67	and	71,	de	novo	CMV	infected)	and	patients	without	an	
asterisk	experienced	GVHD	prior	to	CMV	reactivation.	
**-	human	peptides	may	have	overlapping	areas	of	homology	yielding	a	higher	number	of	matches	
	
	 	
Patients Peptides
n=18 Skin GI Liver Lung Vaginal Muscle Human Matches** CMV Human Immunogenic	CMV CMV Skin GI Liver Lung Vaginal Muscle Skin GI Liver Lung Vaginal Muscle
10* X 58 72 58 47 10 35 10 8
27* X 43 64 55 39 9 35 7 7
45* X X 17 45 26 15 5 15 7 9 6 8
47* X 21 23 22 20 5 19 6 6
48* X X X 24 25 21 21 5 18 5 11 5 4 9 4
67* X X X 28 43 36 24 4 24 3 8 9 3 7 7
68* X X X 10 10 10 10 2 10 2 7 2 2 7 2
70* X 25 28 22 21 5 21 9 8
71* X 29 55 39 28 8 30 2 2
76* X 10 11 11 10 4 10 5 5
79* X 39 49 41 28 7 26 3 2
84* X X 21 25 21 18 4 14 1 7 1 6
90* X X 39 56 43 36 7 27 8 17 7 16
34 X 38 57 47 32 12 31 8 7
38 X 32 47 41 30 6 29 6 6
41 X 12 12 11 11 2 11 5 4
73 X X 5 5 5 5 0 4 1 2 1 2
81 X 10 17 10 6 0 6 4 2
GVHD	Incidence	 GVHD	Tissue	Specific	Peptides GVHD	Tissue	Specific	Gene	ExpressionGenes
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Figures.	
Figure	1.	Proposed	cross-reactivity	model	for	CMV-specific	T	cells	that	may	react	to	matched	
homologous	peptides	(≥6/6	consecutive	amino	acids)	bound	to	the	same	HLA	on	normal	
recipient	cells	present	in	GVHD-affected	tissues.		
	
	
	
Figure	2.		Bioinformatic	pipeline	comparing	alloreactive	peptide	libraries	with	the	CMV	
proteome	for	determination	of	potential	Pro-GVHD	DRP	cross	reactivity	upon	CMV	reactivation	
correlated	with	GVHD-tissue	specific	distribution	of	peptides.	
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Figure	3.	CMV+GVHD	Cross	Reactivity	Potential:	Patient-specific	peak	CMV	peptide	matches	
intersecting	peak	alloreactive	peptides	(IC50<500	nM)	as	a	cross-reactivity	potential	stratified	by	
donor	type	contained	within	each	DRP	alloreactive	peptide	library.		
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Figure	4.	Binding	affinity	similarity	indicated	by	inverse	IC50	values	from	matched	human	and	
CMV	peptides	bound	to	the	same	HLA.	Each	data	point	represents	the	intersection	of	a	matched	
peptide	bound	to	an	HLA	class	I	molecule	(CMVèHuman).	These	peptides	may	be	cross	
reactive,	with	varying	degrees	of	T	cell	cross	reactivity	potential	for	alloreactivity	trigger	to	
ensue	(towards	the	origin	on	the	human	peptide	axis	being	the	greatest).		
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Figure	5A.	CMV-reactivation	course	with	acute	GVHD	onset	and	progression:	Patients	47,	68	and	
70.	Patient	47	exhibited	Grade	IV	GVHD	of	the	GI	tract	(gut)	and	the	other	patients	developed	
steroid	refractory	Grade	IV	gut	GVHD	with	other	organ	involvement.	All	three	patients	showed	
signs	of	CMV	reactivation	and	bursts	of	lymphocytosis	prior	to	GVHD	onset	during	stable	
immunosuppression	(TAC,	Tacrolimus;	SIR,	Sirolimus)	as	measured	by	serum	levels	or	following	
taper.	
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Figure	5B.	CMV-reactivation	with	chronic	GVHD	onset:	Patients	10	and	27.	Patient	10	had	a	
small	spike	reactivation	prior	to	a	more	gradual	lymphocyte	proliferation	during	stable	
immunosuppression	levels	(TAC,	Tacrolimus)	and	would	eventually	develop	relapsed	disease.	
Patient	27	exhibited	a	sharp	reactivation	spike	prior	to	lymphocytosis	at	stable	tacrolimus	levels;	
mainly	skin	and/or	mouth	GVHD	prior	to	DLI	for	both.	
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Figure	5C.	CMV	reactivation/de	novo	infection	in	patients	with	aGVHD	+	cGVHD:	Patients	71	
(new,	continuous	infection	for	200+	days)	and	84	(reactivation).	Patient	71	showed	poor	
lymphoid	recovery,	continuous	low	CMV	infection	and	eventual	relapsed	disease.	Patient	84	
exhibited	low-level	lymphocyte	reactions	following	CMV	reactivation	spikes	and	eventually	
developed	recurrent	gut	and	skin	Grade	IV	GVHD.	Both	patients	received	tacrolimus.	
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Supplementary	Table	1.	Patient	characteristics	
	
CMV	constellation 							All	patients 77	(100)
							D+/R+ 26	(34)
							D-/	R+ 7	(9)
							D+/R- 13	(17)
							D-/	R- 31	(40)
CMV	Prophylaxis 						Acyclovir 56	(73)
						Acyclovir/Valacyclovir 12	(16)
						Valacyclovir 	9	(12)
Age	Distribution 						<40 12	(16)
						40-59 43	(56)
						≥60 22	(29)
Donor 						MRD 26	(34)
						MUD 41	(53)
						MMRD 	1	(1)
						MMUD 9	(12)
Stem	Cell	Source 						Bone	Marrow 7	(9)
						Peripheral	Blood 70	(91)
Diagnosis 					Acute	lymphoid	leukemia 5	(6)
					Acute	myeloid	leukemia 29	(38)
					Chronic	lymphocytic	leukemia							
										and	lymphomas																																									 15	(19)
					Multiple	myeloma 4	(5)
					Myelodysplastic	syndromes																						 24	(31)
Conditioning	Regimen 						Anti-thymocyte	globulin	(ATG) 62	(81)
						Reduced	Intensity 46	(60)
												ATG/TBI 19	(25)
												Busulfan/Fludarabine 27	(35)
												Fludarabine/Melphalan 2	(77)
							Myeloablative 31	(40)
												Busulfan/Cyclophosphamide 17	(22)
												Cyclophosphamide/TBI 11	(14)
												Etoposide/TBI 1	(1)
GVHD	prophylaxis 						Cyclosporin	A/Methotrexate 16	(21)
						Cyclosporin	A/MMF 4	(5)
						Tacrolimus/Methotrexate 34	(44)
						Tacrolimus/MMF 23	(30)
GVHD,	Overall	(n=49) 						Acute,	Grades	I-II 20	(26)
						Acute,	Grades	III-IV 14	(18)
						Chronic 39	(51)
						Both,	Acute	+	Chronic 25	(32)
CMV	&	GVHD	 							CMV,	Before	GVHD	Onset 13	(17)
							CMV,	After	GVHD	Onset 5	(6)
							CMV,	No	GVHD 12	(17)
							No	CMV,		GVHD 31	(40)
							No	CMV,		No	GVHD 16	(20)
Supplemental	Table	1.												Patient	Characteristics,	n	(%)
Total	Transplants 77	(100)									
Gender
																																																																																																																															Total
										Male/Female 43	(55.8)/34	(44.2)
Patient	Age
										Median	(range) 55.6	(21-73)					
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Supplemental	Figure	1.	CMV-seropositive	adjusted	survival	by	CMV	incidence:	GVHD-
independent	effects	of	CMV	post	SCT	
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Appendix	List:	
Appendix	A.	Excel	workbook	–	Sheet	1.	CMV	Proteome	–	NCBI	accession	list	for	hCMV/HHV5		
	 	 	 												Sheet	2.	CMV	Immunogenic	Protein	–	CD8+	List	from	Ref.	#27	
Appendix		B.	Excel	workbook	–	Sheet	1.	Match	Analysis	Summary	–	Total	peptide	#	by	patient	
	 	 	 												Sheet	2.	Match	Analysis	Peptides	–	Screened,	sorted	pt.	peptides		
	
For	access	to	complete	appendices	or	compiled	CMV-Human	peptide	datasets,	please	contact	
the	first	author,	Charles	Hall,	by	email	at	hallce3@vcu.edu	for	further	information.	
